Related Experiment Videos
Science, medicine, and the future. Hypertension
1Clinical Pharmacology Unit, University of Cambridge, Addenbrooke's Hospital. mjb14@medschl.cam.ac.uk
Insights
Essential hypertension, a common condition, remains poorly understood, with genetic factors playing a key role. Molecular genetic analyses offer new insights for personalized treatments and improved patient outcomes.
Area of Science:
- Cardiology
- Genetics
- Nephrology
Background:
- Despite numerous antihypertensive drugs and evidence of stroke risk reduction, the underlying causes of hypertension in most patients remain unknown.
- Current treatments fail to normalize blood pressure in 50% of patients and cannot fully reverse pre-existing cardiac and vascular damage.
- Hypertension is a leading cause of stroke and renal failure, highlighting the need for better understanding and management.
Purpose of the Study:
- To explore the genetic basis of essential hypertension.
- To identify distinct genetic syndromes contributing to hypertension.
- To advance understanding through molecular genetic analyses.
Main Methods:
- Molecular genetic analyses to investigate polygenic and monogenic forms of essential hypertension.
- Analysis of genetic and environmental factor interactions.
- Identification of familial syndromes with multiple affected members.
Main Results:
- Essential hypertension is recognized as a polygenic disease.
- Multiple distinct syndromes are likely involved in hypertension development.
- Interactions between genetic and environmental factors are probable contributors.
- Monogenic syndromes may exist in families with a strong history of hypertension.
Conclusions:
- Recognition of specific hypertension syndromes will enable precise genetic prediction of prognosis.
- Tailored treatment strategies can be developed based on identified genetic factors.
- This research may lead to novel and more effective antihypertensive therapies.
Abstract:
The abundance of drugs now available for treating hypertension, and evidence that small reductions in blood pressure reverse the associated risk of stroke have shifted clinical concerns away from hypertension. However, we do not understand the cause of hypertension in 95% of patients, fail to achieve a normal blood pressure in 50% of patients, and are unable fully to reverse the cardiac and vascular changes that predate the diagnosis and treatment of hypertension. Consequently, hypertension remains the commonest cause of strokes in Britain and of renal failure in the United States. Essential hypertension is a polygenic disease whose understanding can now be advanced through molecular genetic analyses. Several different syndromes are likely to be recognised; most will be due to interactions between genetic and environmental factors, but there are also likely to be further monogenic syndromes in families with multiple affected members. Recognition of these syndromes will permit accurate genetic prediction of prognosis and optimal treatment and perhaps lead to new and more powerful classes of antihypertensive treatment.